Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 1.00 |
| ▸ | CPT2 | P23786 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HMGCR | P04035 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | BHMT | Q93088 | 3/20 | 0.43 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.39 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523390 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL8037883 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL1832938 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL1834211 | 1.00 | FFAR1 (1.00) | FFAR1CPT2TDP1KDM4EHMGCR | |
| SCHEMBL14810357 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1KDM4EADRA1A | |
| SCHEMBL22748728 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL742996 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL22748689 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1TSHRALDH1A1 | |
| SCHEMBL2496692 | 0.91 | TDP1 (0.83) | FFAR1CPT2TDP1KDM4EADRA1A | |
| SCHEMBL6697555 | 0.91 | FFAR1 (0.83) | FFAR1CPT2TDP1KDM4EHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076577-A2 | METHODS FOR MODULATING CELL PLURIPOTENCY AND SELF-RENEWAL PROPERTY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-04 | — | — | WO | claimed |
| US-20220218659-A1 | PI3K/LYN-ACLY Signaling Inhibition | INSTITUTE FOR CANCER RESEARCH D/B/A THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | 2022-07-14 | — | — | US | claimed |
| US-20210137934-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2021-05-13 | — | — | US | claimed |
| US-10512624-B2 | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 | SYNDROMEX LTD. (IL) | 2019-12-24 | — | — | US | claimed |
| WO-2018170316-A1 | METHODS OF IDENTIFYING MYC-DRIVEN AND LIPOGENESIS-DEPENDENT NEOPLASMS AND METHODS OF TREATING THE SAME | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2018-09-20 | — | — | WO | claimed |
| US-20180235918-A1 | Long-Chain Amphipathic Dicarboxylic Acids for Treatment of Diabetes Type-1 | SYNDROMEX LTD. (IL) | 2018-08-23 | — | — | US | claimed |
| EP-1001755-B1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNDROME X LTD (IL) | 2011-05-11 | — | — | EP | claimed |
| US-20100240683-A1 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | SYNDROMEX LTD. (IL) | 2010-09-23 | — | — | US | claimed |
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | SYNDROMEX LTD. C/O YISSUM RESEARCH DEVELOPMENT COMPANY, OF (IL) | 2010-05-06 | — | — | US | claimed |
| EP-2131832-A2 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | Syndromex Ltd. (IL) | 2009-12-16 | — | — | EP | claimed |
| WO-2008104976-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | SYNDROMEX LTD. (IL) | 2008-09-04 | — | — | WO | claimed |
| WO-2008104975-A2 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | SYNDROMEX LTD. (IL) | 2008-09-04 | — | — | WO | claimed |
| US-20040171585-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20040171688-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | BAR-TANA JACOB (IL) | 2004-09-02 | — | — | US | claimed |
| US-20020037876-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | YISSUM RESEARCH DEVELOPMENT COMPANY OF HEBREW UNIVERSITY OF JERUSALEM | 2002-03-28 | — | — | US | claimed |
| US-4634795-A | TREATMENT OF OBESITY, HYPERLIPIDEMIA, AND MATURITY-ONSET DIABETES | EPIS S.A. (CH) | 1987-01-06 | — | — | US | claimed |
| EP-0081930-B1 | LONG-CHAIN ALPHA, OMEGA-DICARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Epis S.A. (CH) | 1986-07-30 | — | — | EP | claimed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | claimed |
| EP-4281058-B1 | FUNCTIONALIZED LONG-CHAIN DICARBOXYLIC ACIDS, AND THEIR USE FOR TREATMENT OF KIDNEY DISEASES | ESPERVITA THERAPEUTICS INC (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-0081930-A1 | Long-chain alpha, omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Epis S.A. (CH) | 1983-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10512624-B2 | Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 | IAPP, SLC27A1, SLC16A1 | FFAR1 91/4885CPT2 84/4885TDP1 1552/4885 |
| US-20100240683-A1 | COMBINATION THERAPY, COMPOSITION AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS | HMGCR, APOB, CETP | FFAR1 71/4885CPT2 45/4885TDP1 2506/4885 |
| US-20100113599-A1 | AMPHIPATHIC CARBOXYLATES FOR THE TREATMENT OF IMMUNE-RELATED DISORDERS | MALT1, TLR9, TLR6 | FFAR1 157/4885CPT2 134/4885TDP1 1097/4885 |
| US-20180235918-A1 | Long-Chain Amphipathic Dicarboxylic Acids for Treatment of Diabetes Type-1 | IAPP, SLC27A1, SLC16A1 | FFAR1 91/4885CPT2 84/4885TDP1 1552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.